TY - JOUR
T1 - TERT Promoter Mutations and Risk of Recurrence in Meningioma
AU - Sahm, Felix
AU - Schrimpf, Daniel
AU - Olar, Adriana
AU - Koelsche, Christian
AU - Reuss, David
AU - Bissel, Juliane
AU - Kratz, Annekathrin
AU - Capper, David
AU - Schefzyk, Sebastian
AU - Hielscher, Thomas
AU - Wang, Qianghu
AU - Sulman, Erik P.
AU - Adeberg, Sebastian
AU - Koch, Arend
AU - Okuducu, Ali Fuat
AU - Brehmer, Stefanie
AU - Schittenhelm, Jens
AU - Becker, Albert
AU - Brokinkel, Benjamin
AU - Schmidt, Melissa
AU - Ull, Theresa
AU - Gousias, Konstantinos
AU - Kessler, Almuth Friederike
AU - Lamszus, Katrin
AU - Debus, Jürgen
AU - Mawrin, Christian
AU - Kim, Yoo Jin
AU - Simon, Matthias
AU - Ketter, Ralf
AU - Paulus, Werner
AU - Aldape, Kenneth D.
AU - Herold-Mende, Christel
AU - Von Deimling, Andreas
N1 - Publisher Copyright:
© The Author 2015. Published by Oxford University Press. All rights reserved.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - The World Health Organization (WHO) classification and grading system attempts to predict the clinical course of meningiomas based on morphological parameters. However, because of high interobserver variation of some criteria, more reliable prognostic markers are required. Here, we assessed the TERT promoter for mutations in the hotspot regions C228T and C250T in meningioma samples from 252 patients. Mutations were detected in 16 samples (6.4% across the cohort, 1.7%, 5.7%, and 20.0% of WHO grade I, II, and III cases, respectively). Data were analyzed by t test, Fisher's exact test, log-rank test, and Cox proportional hazard model. All statistical tests were two-sided. Within a mean follow-up time in surviving patients of 68.1 months, TERT promoter mutations were statistically significantly associated with shorter time to progression (P <. 001). Median time to progression among mutant cases was 10.1 months compared with 179.0 months among wild-type cases. Our results indicate that the inclusion of molecular data (ie, analysis of TERT promoter status) into a histologically and genetically integrated classification and grading system for meningiomas increases prognostic power. Consequently, we propose to incorporate the assessment of TERT promoter status in upcoming grading schemes for meningioma.
AB - The World Health Organization (WHO) classification and grading system attempts to predict the clinical course of meningiomas based on morphological parameters. However, because of high interobserver variation of some criteria, more reliable prognostic markers are required. Here, we assessed the TERT promoter for mutations in the hotspot regions C228T and C250T in meningioma samples from 252 patients. Mutations were detected in 16 samples (6.4% across the cohort, 1.7%, 5.7%, and 20.0% of WHO grade I, II, and III cases, respectively). Data were analyzed by t test, Fisher's exact test, log-rank test, and Cox proportional hazard model. All statistical tests were two-sided. Within a mean follow-up time in surviving patients of 68.1 months, TERT promoter mutations were statistically significantly associated with shorter time to progression (P <. 001). Median time to progression among mutant cases was 10.1 months compared with 179.0 months among wild-type cases. Our results indicate that the inclusion of molecular data (ie, analysis of TERT promoter status) into a histologically and genetically integrated classification and grading system for meningiomas increases prognostic power. Consequently, we propose to incorporate the assessment of TERT promoter status in upcoming grading schemes for meningioma.
UR - http://www.scopus.com/inward/record.url?scp=84968717793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84968717793&partnerID=8YFLogxK
U2 - 10.1093/jnci/djv377
DO - 10.1093/jnci/djv377
M3 - Article
C2 - 26668184
AN - SCOPUS:84968717793
SN - 0027-8874
VL - 108
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 5
M1 - djv377
ER -